Print

AstraZeneca-Amgen asthma drug succeeds in late-stage oesophagus disease trial

AI generated image

AstraZeneca said on Thursday its asthma drug Tezspire met the main goals of a late-stage trial in patients with a chronic inflammatory disorder of the oesophagus, offering a boost after a string of pipeline setbacks.

The study showed that Tezspire, developed with Amgen, significantly reduced inflammation in the oesophagus and eased difficulty in swallowing compared with a placebo in patients suffering with eosinophilic esophagitis, which affects more than 470,000 people in the United States.

CEO Pascal Soriot is steering AstraZeneca towards its target of $80 billion in annual sales by 2030, counting on up to 20 new drug launches as the company grapples with patent expiries and geopolitical challenges.

But the drugmaker has suffered several recent setbacks. In July, Wainua unexpectedly failed a heart disease trial, while a late-stage study of rare disease drug Ultomiris also failed. In May, a U.S. regulatory panel rejected its breast cancer drug camizestrant on trial design grounds.

AstraZeneca also halted an advanced study of experimental lung cancer drug volrustomig this month after a committee overseeing the trial said it was unlikely to meet its main goal.

The company’s shares were down 0.5% by 0729 GMT on Thursday, having fallen 14% since Wainua’s trial failure.

While the Tezspire results were encouraging, investors remain focused on upcoming results from two cancer trials that are seen as critical to AstraZeneca’s pipeline and to lifting pressure on the shares.

Tezspire is a monoclonal antibody that blocks a protein known as TSLP, which can trigger inflammation in conditions driven by eosinophils, a type of white blood cell, as well as severe asthma.

The drug is already approved in the United States, European Union and other countries as an add-on treatment for severe asthma and competes with Sanofi and Regeneron’s blockbuster drug Dupixent.

Tezspire generated $1.13 billion in sales for AstraZeneca in 2025.

(Reuters)

RELATED ARTICLES

48 mins ago | ind vs nz

NZ skipper Latham highlights Bumrah challenge; hails Kiwis pace “leader” Matt Henry ahead of 1st Test against India

New Zealand skipper Tom Latham spoke on Kiwis facing Indian pace superstar Jasprit Bumrah, saying that his unique action is going to make facing him a huge challenge. Following India's series wins in the T20I and ODI legs of the series, the inaugu...

49 mins ago | Finance and Contract Committee

Municipal Corporation of Gurugram approves development projects worth Rs 61 crore

The Municipal Corporation of Gurugram (MCG) has approved development projects and civic amenities worth over Rs 61.10 crore at the 11th meeting of its Finance and Contract Committee (F&CC), an official said. The meeting was held on Tuesday under...

54 mins ago | US and Iran

US, Iran exchange fire despite talks with mediators

The US and Iran exchanged fire on Tuesday, with the US striking an Iranian missile launch site after Iran said it targeted a US military radar system in Bahrain, despite talks between Iran and mediators Oman and Qatar. The latest back-and-forth betw...